Skip to content
The START Center for Cancer Research - Logo
  • Services
    • Preclinical
    • Early Phase
  • Who We Serve
    • Patients
    • Pharma
    • Hospitals & Oncology Practices
  • START Locations
    • START San Antonio
    • START Midwest
    • START Mountain Region
    • START Carolinas
    • START Madrid – CIOCC
    • START Madrid – FJD
    • START Barcelona
    • START Rioja
    • START Lisbon
    • START Dublin
  • About
    • Company
    • Leadership
    • Principal Investigators
    • Careers
    • Resources
      • Blog
      • Events
      • Newsroom
      • Patient Stories
      • Press
      • Publications
      • Webinars
    • Contact
  • Patients & Family
    • Explore Clinical Trials
    • About Clinical Trials
    • Patient Stories
  • Referring Physicians
  • Find a Trial
  • Services
    • Preclinical
    • Early Phase
  • Who We Serve
    • Patients
    • Pharma
    • Hospitals & Oncology Practices
  • START Locations
    • START San Antonio
    • START Midwest
    • START Mountain Region
    • START Carolinas
    • START Madrid – CIOCC
    • START Madrid – FJD
    • START Barcelona
    • START Rioja
    • START Lisbon
    • START Dublin
  • About
    • Company
    • Leadership
    • Principal Investigators
    • Careers
    • Resources
      • Blog
      • Events
      • Newsroom
      • Patient Stories
      • Press
      • Publications
      • Webinars
    • Contact
  • Patients & Family
    • Explore Clinical Trials
    • About Clinical Trials
    • Patient Stories
  • Referring Physicians
  • Find a Trial

Histology-agnostic drugs: A paradigm shift – A narrative review

  • Home
  •   |  
  • Publication
  •   |  
  • Histology-agnostic drugs: A paradigm shift – A narrative review
Home   |   Publication   |   Histology-agnostic drugs: A paradigm shift – A narrative review
Publications
75 +
Clinical Trials Ran
0 +
Approved Therapies
0

Areas of Expertise

PrevPrev. Principal InvestigatorAtezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Next Principal InvestigatorA First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNext
Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Contact Us
default-logo
Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.

Who We Serve

  • Patients
  • Pharma
  • Hospitals & Oncology Practices

Services

  • Preclinical
  • Early Phase

About

  • Company
  • Leadership
  • Principal Investigators
  • Careers
  • Contact

Resources

  • Blog
  • Events
  • Newsroom
  • Patient Stories
  • Press
  • Publications
  • Webinars

START Locations

  • START - San Antonio
  • START - Midwest
  • START - Mountain Region
  • START - Carolinas
  • START - Madrid - CIOCC
  • START - Madrid - FJD
  • START - Barcelona
  • START - Rioja
  • START - Lisbon
  • START - Dublin

Patients & Family

  • Explore Clinical Trials
  • About Clinical Trials
  • Patient Stories
  • Referring Physicians
Find a Trial
The START Center for Cancer Research - Logo

© 2025 START Research. All rights reserved.

Facebook Linkedin X-twitter
  • Privacy Policy
  • Cookie Policy
  • Site Map